Metastatic Melanoma Clinical Trial
Official title:
A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
Verified date | April 2020 |
Source | Canadian Cancer Trials Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Studies have shown that the study drug, pembrolizumab, works by helping the immune system. In this way, pembrolizumab may help to slow the growth of melanoma or may cause cancer cells to die. Compared to standard treatments, pembrolizumab seems to lengthen the time patients lived overall and the time without their cancer getting worse.
Status | Terminated |
Enrollment | 9 |
Est. completion date | September 30, 2019 |
Est. primary completion date | March 22, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed melanoma that is recurrent/metastatic and not amenable to potentially curative surgery. - Presence of clinically and/or radiologically documented disease based on RECIST 1.1. At least one site of disease must be unidimensionally measurable by contrast-enhanced CT scan as follows: CT scan (with slice thickness of = 5 mm) = 10 mm --> longest diameter Lymph nodes by CT scan = 15 mm --> measured in short axis - Age = 18 years. - ECOG Performance Status of 0 to 1. - Previous Therapy Surgery: Previous surgery is permitted provided that it has been at least 21 days prior to patient registration and that wound healing has occurred. Systemic Therapy: Patients may not have received any prior systemic therapy for metastatic melanoma. Radiation: Palliative radiation is permitted provided > 7 days has elapsed between last dose and enrollment on the trial. - Laboratory Requirements Absolute neutrophils = 1.5 x 10^9/L Platelets = 100 x 10^9/L Hemoglobin = 90 g/L or = 5.6 mmol/L (without transfusion or EPO dependency) Serum creatinine or measured or calculated creatinine: =1.5 x ULN or = 60 mL/min for subject with creatinine clearance levels > 1.5 x ULN Serum Total Bilirubin = 1.5 x ULN or Direct bilirubin = ULN for subjects with total bilirubin levels > 1.5 x ULN AST and ALT = 2.5 x ULN (= 5 x ULN for subjects with liver mets) Albumin = 25 g/L - Women/men of childbearing potential must have agreed to use a highly effective contraceptive method. - Women of childbearing potential will have a serum or urine pregnancy test within 7 days prior to registration to determine eligibility. - Patient consent must be obtained according to local Institutional and/or University Human Experimental Committee requirements. - Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre. Exclusion Criteria: - Patients who have received prior systemic treatment for metastatic melanoma. - Patients with known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). - Patients with a known history of or known positive for Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA [qualitative] is detected). Patients with unknown history of Hepatitis B virus (HBV) or Hepatitis C virus (HCV) will require screening. - Patients with previously treated brain metastases may participate provided they are stable with no evidence of enlargement following radiation treatment and no acute radiation toxicity OR no evidence of enlargement at least 4 weeks prior to the first dose of study drug if untreated and are off systemic steroids for at least two weeks. - Patients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 4 months after the last dose of trial treatment. - Patients who previously had a severe hypersensitivity reaction to treatment with another mAb. - Patients with an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. (Only patients on active treatment are ineligible). - Patients with a history of a malignancy (other than the disease under treatment in the study) within 5 years prior to first study drug administration. - Patients on any systemic corticosteroid therapy within one week before the planned date for first dose of treatment or on any other form of immunosuppressive medication. - Patients with an allergy to iodinated contrast media used for CT. - Patients with a known history of active TB (Bacillus Tuberculosis). - Patients with evidence of interstitial lung disease; - Patients with known history of, or any evidence of active, non-infectious pneumonitis |
Country | Name | City | State |
---|---|---|---|
Canada | Kingston Health Sciences Centre | Kingston | Ontario |
Canada | London Regional Cancer Program | London | Ontario |
Canada | Ottawa Hospital Research Institute | Ottawa | Ontario |
Canada | Allan Blair Cancer Centre | Regina | Saskatchewan |
Canada | Odette Cancer Centre | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Canadian Cancer Trials Group | Merck Sharp & Dohme LLC |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of Tumor Texture by CT Scan | To assess whether tumour texture parameters from a CT scan can differentiate patients who do and who do not respond to treatment with pembrolizumab. Trial closed due to slow accrual, analysis was no done for the primary outcome because data were not collected. | 12 months | |
Secondary | Overall Response Rate Assessed by CT Scan | To determine the overall response rate (complete + partial response)/total number of patients.
Response and progression will be evaluated in this study using the revised international criteria (1.1) proposed by the RECIST (Response Evaluation Criteria in Solid Tumours) committee as well as the modified iRECIST guidelines. Response were assessed by CT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02224781 -
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05388877 -
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT05103891 -
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
|
Phase 1 | |
Completed |
NCT00414765 -
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
|
Phase 4 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Completed |
NCT01621490 -
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
|
Phase 1 | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT04940299 -
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02278887 -
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT02360579 -
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
|
Phase 2 | |
Terminated |
NCT02521870 -
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT02177110 -
A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
|
||
Withdrawn |
NCT01340729 -
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01416844 -
Study of Immune Responses in Patients With Metastatic Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00984464 -
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00631618 -
Clinical Trial of Sutent to Treat Metastatic Melanoma
|
Phase 2 | |
Terminated |
NCT00571116 -
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
|
Phase 1 | |
Recruiting |
NCT00226473 -
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
|
Phase 4 |